<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02157259</url>
  </required_header>
  <id_info>
    <org_study_id>SEA-050 Sepsis Study</org_study_id>
    <nct_id>NCT02157259</nct_id>
  </id_info>
  <brief_title>An Observational Study of the Causes, Management, and Outcomes of Community-acquired Sepsis and Severe Sepsis in Southeast Asia</brief_title>
  <acronym>SEA050</acronym>
  <official_title>An Observational Study of the Causes, Management, and Outcomes of Community-acquired Sepsis and Severe Sepsis in Southeast Asia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>FHI 360</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Social &amp; Scientific Systems Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study to identify the etiology, management, and outcome of
      community-acquired sepsis and severe sepsis in children and adults in Southeast Asia. The
      study will take place in Thailand, Vietnam, and Indonesia, the partner countries of SEAICRN.
      Potential study patients will be any patients (both children and adults) who are presented at
      the hospital with community-acquired sepsis or severe sepsis and require hospitalization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll 2,250 total patients with sepsis or severe sepsis patients up to 2
      years of study. 750 patients will be enrolled in each of Thailand, Vietnam, and Indonesia.
      There will be 3 sites in each country and some sites will function as cluster/unit sites
      linking up to 3 hospitals as one 'site' to enable adequate enrollment of both adult and
      pediatric cases.

      Primary objective of the study is to determine the causes of community-acquired sepsis and
      severe sepsis in adult and pediatric subjects across Southeast Asia.

      The secondary objectives are as follow:

        -  To define the current acute management (within the first 48 hours after admission) of
           subjects presenting with community-acquired sepsis and severe sepsis and gaps of current
           practice as defined by the surviving sepsis campaign 2012. This will provide the basis
           for designing practical interventions to reduce the mortality of subjects with sepsis
           and severe sepsis in the future.

        -  To define the clinical outcomes of community-acquired sepsis and severe sepsis in
           Southeast Asia.

        -  To identify risk factors associated with sepsis or severe sepsis.

        -  To determine the extent of antimicrobial resistance in organisms that cause
           community-acquired sepsis and severe sepsis in Southeast Asia and to determine the
           association between antimicrobial resistance and mortality.

        -  To evaluate the accuracy of selected rapid diagnostic tests (RDTs) in determining the
           causes of community-acquired sepsis and severe sepsis compared to well-defined gold
           standard tests.

      As this is an observational study and not a clinical trial, researchers will not be involved
      in the management, care and treatment of study subjects. This will remain the responsibility
      of the attending medical staff according to standard of care (SOC) in the participating
      hospitals. Therefore the research study will not influence patient management. SOC for sepsis
      and severe sepsis in each subject will be recorded, and will be reported as summary
      statistics at the end of the study. This will not be used to influence the management and
      care of sepsis and severe sepsis cases at the participating hospitals during the study
      period, but will be used to guide the improvement of the SOC after the study is complete.

      NOTE: EACH INSTITUTION IN THIS STUDY IS ITS OWN SPONSOR AS LISTED BELOW:

        1. Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

        2. Queen Sirikit National Institute of Child Health, Bangkok, Thailand.

        3. Children's Hospital 1 Ho Chi Minh City, Vietnam.

        4. Children's Hospital 2 Ho Chi Minh City, Vietnam.

        5. Hospital for Tropical Diseases Ho Chi Minh City, Vietnam.

        6. National Hospital for Pediatrics Hanoi, Vietnam.

        7. National Hospital for Tropical Diseases, Hanoi, Vietnam.

        8. Hue Central Hospital, Hue City, Vietnam.

        9. Dr. Wahidin Soedirohusodo Hospital Makassar, Indonesia.

       10. Dr. Sardjito Hospital Yogyakarta, Indonesia.

       11. Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia

       12. Sappasithiprasong Hospital Ubonratchathani, Thailand

       13. Chiangrai Prachanukroh Hospital, Chiangrai Thailand

       14. University of Oxford, United Kingdom
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The etiology of community-acquired sepsis and severe sepsis expressed in percentages of enrolled subjects.</measure>
    <time_frame>Total length of time that subjects will be in the study is 28 to 35 days.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time from hospital admission to any systemic antibiotic administration.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of initial systemic antimicrobial effective to treat the cause of the infection.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects receiving fluid challenge (giving bolus of fluid) if the patient has hypotension.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects receiving adequate ventilatory support (including percentage of subjects receiving supplemental oxygen, percentage of subjects receiving Positive-end Expiratory Pressure (PEEP).</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects receiving low-volume lung-protective ventilation.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects receiving arterial blood gas evaluation).</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects receiving renal replacement therapies (including hemodialysis and peritoneal dialysis).</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects receiving imaging to determine source or deep foci of infection (including chest radiography, ultrasonogram, CT scan and MRI).</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects receiving evaluation by scoring system.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects receiving stress prophylaxis.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients receiving deep vein thrombosis (DVT) prophylaxis.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects receiving treatment in ICUs.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day mortality rate.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects developing major organ dysfunction; for example ventilatory failure and renal failure.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors associated with sepsis or severe sepsis</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of antimicrobial resistance and its association with appropriate empirical therapy and outcomes.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivities and specificities of selected RDTs in determining the causes of community-acquired sepsis and severe sepsis</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">2250</enrollment>
  <condition>Sepsis</condition>
  <condition>Severe Sepsis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female patients, age 30 days on the day of enrollment with community-acquired
        sepsis or severe sepsis in Southeast Asia. Of the 2,250 enrolled patients, 1,125 will be
        adults and 1,125 will be children.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥30 days old and weighing at least 3 kg or more on the day of enrollment into the
             study

          2. Required hospitalization as decided by the attending physician

          3. Documented by attending physician that an infection is the primary cause of illness
             leading to the hospitalization. These can be infections due to any pathogens
             (bacteria, viruses, fungi and parasites).

          4. Presence of Systemic Inflammatory Response Syndrome (SIRS):

             4.1 For adults (≥ 18 years old), any combination of a minimum of any 3 of the
             following 20 parameters

               -  Fever or hypothermia (Core body temperature defined as &gt;38.3 C or &lt;36.0 C)

               -  Tachycardia (heart rate &gt;90 beats per minute)

               -  Tachypnea (respiratory rate &gt;20 per minute)

               -  Arterial hypotension (systolic blood pressure (SBP) &lt;90 mmHg, mean arterial
                  pressure (MAP) &lt;70 mmHg, or SBP decrease &gt;40 mmHg)

               -  White blood cell (WBC) &gt;12,000 u/L or &lt;4000 u/L or immature forms &gt;10%

               -  Platelet count &lt;100,000 u/L

               -  Altered mental status with Glasgow Coma Score (GCS) &lt;15

               -  Hypoxemia (Pulse Oximetry Level &lt;95)

               -  Ileus

               -  Significant edema or positive fluid balance

               -  Decreased capillary refill or mottling

               -  Hyperglycemia (plasma glucose &gt;140 mg/dL) in the absence of diabetes

               -  Plasma C-reactive protein &gt;2 SD above the normal value

               -  Plasma procalcitonin &gt; 2 SD above the normal value

               -  Arterial hypoxemia (PaO2 / FIO2 &lt;300)

               -  Acute oliguria (urine output &lt;0.5 mL/kg/hr or 45 mmol/L for 2 hours)

               -  Creatinine increase &gt;0.5 mg/dL

               -  INR &gt;1.5 or a PTT &gt;60 seconds

               -  Plasma total bilirubin &gt;4 mg/dl or 70 mmol/L

               -  Hyperlactatemia (&gt;1 mmol/L)

             4.2 For pediatric patients (&gt;30 days old and &lt;18 years old), all of the 3 following
             symptoms:

               -  Fever or hypothermia (rectal temperature defined as &gt;38.5 C or &lt;35.0 C [or
                  equivalent])

               -  Tachycardia (heart rate &gt;2 SD above the normal value for age). This could be
                  absent in hypothermic subject.

               -  Tachypnea (respiratory rate &gt;2 SD above the normal value for age)

             AND at least one of the following parameters:

               -  Altered mental status,(e.g., drowsiness, poor quality of cry, poor reaction to
                  parent stimuli, and poor response to social overtures)

               -  Systolic blood pressure &lt;2 SD below the normal value for age OR narrow pulse
                  pressure (&lt;20 mmHg) OR poor perfusion (capillary refill &gt;2 sec)

               -  Hypoxemia (Pulse Oximetry Level &lt;95)

               -  White blood cell &gt;15,000 u/L or &lt;5,000 u/L or immature forms &gt;10%.

          5. Informed Consent has been obtained.

        Exclusion Criteria:

          -  Admitted to the study site hospital for this current episode for more than 24 hours
             before enrollment.

          -  Hospitalized for this current episode for more than 72 hours at another
             primary/referring hospital.

          -  Prior to this current episode, the subject was admitted to any hospital within the
             last 30 days.

          -  An underlying pre-existing condition is thought to have led to or contributed to this
             sepsis episode. For example, sepsis is considered to be directly attributable to
             existing non-infectious conditions such as stroke, cardiovascular diseases, acute
             myocardial infarction, cancer, burn, injury, and trauma.

          -  Prior to enrollment, it is documented by the attending physician that hospital
             acquired infection is associated with the cause of the sepsis or severe sepsis.

          -  The subject has been enrolled into this study or another sepsis study before.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Direk Limmathurotsakul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol Oxford Tropical Medicine Research Unit (MORU), Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Sardjito Hospital</name>
      <address>
        <city>Yogyakarta</city>
        <state>DI Yogyakarta</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cipto Mangunkusumo Hospital</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jaya</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Wahidin Soedirohusodo</name>
      <address>
        <city>Makasar</city>
        <state>Sulawesi Selatan</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitas Hasanuddin</name>
      <address>
        <city>Makassar</city>
        <state>Sulawesi Selatan</state>
        <zip>90245</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Unit Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Sirikit National Institute of Child Health</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiangrai Prachanukroh Hospital</name>
      <address>
        <city>Chiangrai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sappasitthiprasong Hospital</name>
      <address>
        <city>Ubon Ratchathani</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital of Paediatric</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital of Tropical Diseases</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children Hospital 1</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children Hospital 2</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Tropical Diseases</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hue Central Hospital</name>
      <address>
        <city>Hue City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
    <country>Thailand</country>
    <country>Vietnam</country>
  </location_countries>
  <reference>
    <citation>World Health Organization (2008) The global burden of disease: 2004 update.</citation>
  </reference>
  <reference>
    <citation>Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL; International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008 Jan;36(1):296-327. Erratum in: Crit Care Med. 2008 Apr;36(4):1394-6.</citation>
    <PMID>18158437</PMID>
  </reference>
  <reference>
    <citation>Maitland K, Kiguli S, Opoka RO, Engoru C, Olupot-Olupot P, Akech SO, Nyeko R, Mtove G, Reyburn H, Lang T, Brent B, Evans JA, Tibenderana JK, Crawley J, Russell EC, Levin M, Babiker AG, Gibb DM; FEAST Trial Group. Mortality after fluid bolus in African children with severe infection. N Engl J Med. 2011 Jun 30;364(26):2483-95. doi: 10.1056/NEJMoa1101549. Epub 2011 May 26.</citation>
    <PMID>21615299</PMID>
  </reference>
  <reference>
    <citation>Cheng AC, West TE, Limmathurotsakul D, Peacock SJ. Strategies to reduce mortality from bacterial sepsis in adults in developing countries. PLoS Med. 2008 Aug 19;5(8):e175. doi: 10.1371/journal.pmed.0050175.</citation>
    <PMID>18752342</PMID>
  </reference>
  <reference>
    <citation>Suttinont C, Losuwanaluk K, Niwatayakul K, Hoontrakul S, Intaranongpai W, Silpasakorn S, Suwancharoen D, Panlar P, Saisongkorh W, Rolain JM, Raoult D, Suputtamongkol Y. Causes of acute, undifferentiated, febrile illness in rural Thailand: results of a prospective observational study. Ann Trop Med Parasitol. 2006 Jun;100(4):363-70.</citation>
    <PMID>16762116</PMID>
  </reference>
  <reference>
    <citation>Gasem MH, Wagenaar JF, Goris MG, Adi MS, Isbandrio BB, Hartskeerl RA, Rolain JM, Raoult D, van Gorp EC. Murine typhus and leptospirosis as causes of acute undifferentiated fever, Indonesia. Emerg Infect Dis. 2009 Jun;15(6):975-7. doi: 10.3201/eid1506.081405.</citation>
    <PMID>19523308</PMID>
  </reference>
  <reference>
    <citation>Phongmany S, Rolain JM, Phetsouvanh R, Blacksell SD, Soukkhaseum V, Rasachack B, Phiasakha K, Soukkhaseum S, Frichithavong K, Chu V, Keolouangkhot V, Martinez-Aussel B, Chang K, Darasavath C, Rattanavong O, Sisouphone S, Mayxay M, Vidamaly S, Parola P, Thammavong C, Heuangvongsy M, Syhavong B, Raoult D, White NJ, Newton PN. Rickettsial infections and fever, Vientiane, Laos. Emerg Infect Dis. 2006 Feb;12(2):256-62.</citation>
    <PMID>16494751</PMID>
  </reference>
  <reference>
    <citation>Hoa NT, Diep TS, Wain J, Parry CM, Hien TT, Smith MD, Walsh AL, White NJ. Community-acquired septicaemia in southern Viet Nam: the importance of multidrug-resistant Salmonella typhi. Trans R Soc Trop Med Hyg. 1998 Sep-Oct;92(5):503-8.</citation>
    <PMID>9861362</PMID>
  </reference>
  <reference>
    <citation>Wijedoru LP, Kumar V, Chanpheaktra N, Chheng K, Smits HL, Pastoor R, Nga TV, Baker S, Wuthiekanun V, Peacock SJ, Putchhat H, Parry CM. Typhoid fever among hospitalized febrile children in Siem Reap, Cambodia. J Trop Pediatr. 2012 Feb;58(1):68-70. doi: 10.1093/tropej/fmr032. Epub 2011 Apr 20.</citation>
    <PMID>21508082</PMID>
  </reference>
  <reference>
    <citation>Suputtamongkol Y, Hall AJ, Dance DA, Chaowagul W, Rajchanuvong A, Smith MD, White NJ. The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand. Int J Epidemiol. 1994 Oct;23(5):1082-90.</citation>
    <PMID>7860160</PMID>
  </reference>
  <reference>
    <citation>Limmathurotsakul D, Wongratanacheewin S, Teerawattanasook N, Wongsuvan G, Chaisuksant S, Chetchotisakd P, Chaowagul W, Day NP, Peacock SJ. Increasing incidence of human melioidosis in Northeast Thailand. Am J Trop Med Hyg. 2010 Jun;82(6):1113-7. doi: 10.4269/ajtmh.2010.10-0038.</citation>
    <PMID>20519609</PMID>
  </reference>
  <reference>
    <citation>Bhengsri S, Baggett HC, Jorakate P, Kaewpan A, Prapasiri P, Naorat S, Thamthitiwat S, Tanwisaid K, Chantra S, Salika P, Dejsirilert S, Peruski LF, Maloney SA. Incidence of bacteremic melioidosis in eastern and northeastern Thailand. Am J Trop Med Hyg. 2011 Jul;85(1):117-20. doi: 10.4269/ajtmh.2011.11-0070.</citation>
    <PMID>21734135</PMID>
  </reference>
  <reference>
    <citation>Hashairi F, Hasan H, Azlan K, Deris ZZ. An eight-year review of blood culture and susceptibility among sepsis cases in an emergency department in Northeastern Malaysia. Trop Biomed. 2011 Dec;28(3):599-605.</citation>
    <PMID>22433889</PMID>
  </reference>
  <reference>
    <citation>Deen J, von Seidlein L, Andersen F, Elle N, White NJ, Lubell Y. Community-acquired bacterial bloodstream infections in developing countries in south and southeast Asia: a systematic review. Lancet Infect Dis. 2012 Jun;12(6):480-7. doi: 10.1016/S1473-3099(12)70028-2. Review.</citation>
    <PMID>22632186</PMID>
  </reference>
  <reference>
    <citation>Angkasekwinai N, Rattanaumpawan P, Thamlikitkul V. Epidemiology of sepsis in Siriraj Hospital 2007. J Med Assoc Thai. 2009 Mar;92 Suppl 2:S68-78.</citation>
    <PMID>19562989</PMID>
  </reference>
  <reference>
    <citation>Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM; Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004 Mar;32(3):858-73. Review. Erratum in: Crit Care Med. 2004 Oct;32(10):2169-70. Crit Care Med. 2004 Jun;32(6):1448. Dosage error in article text.</citation>
    <PMID>15090974</PMID>
  </reference>
  <reference>
    <citation>Phua J, Koh Y, Du B, Tang YQ, Divatia JV, Tan CC, Gomersall CD, Faruq MO, Shrestha BR, Gia Binh N, Arabi YM, Salahuddin N, Wahyuprajitno B, Tu ML, Wahab AY, Hameed AA, Nishimura M, Procyshyn M, Chan YH; MOSAICS Study Group. Management of severe sepsis in patients admitted to Asian intensive care units: prospective cohort study. BMJ. 2011 Jun 13;342:d3245. doi: 10.1136/bmj.d3245.</citation>
    <PMID>21669950</PMID>
  </reference>
  <reference>
    <citation>Khwannimit B, Bhurayanontachai R. The epidemiology of, and risk factors for, mortality from severe sepsis and septic shock in a tertiary-care university hospital setting. Epidemiol Infect. 2009 Sep;137(9):1333-41. doi: 10.1017/S0950268809002027. Epub 2009 Feb 4.</citation>
    <PMID>19192320</PMID>
  </reference>
  <reference>
    <citation>Kanoksil M, Jatapai A, Peacock SJ, Limmathurotsakul D. Epidemiology, microbiology and mortality associated with community-acquired bacteremia in northeast Thailand: a multicenter surveillance study. PLoS One. 2013;8(1):e54714. doi: 10.1371/journal.pone.0054714. Epub 2013 Jan 18. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/e199ebcc-0bc1-4be1-ad91-ad2a8c0c9382.</citation>
    <PMID>23349954</PMID>
  </reference>
  <reference>
    <citation>Hof H. An update on the medical management of listeriosis. Expert Opin Pharmacother. 2004 Aug;5(8):1727-35. Review.</citation>
    <PMID>15264987</PMID>
  </reference>
  <reference>
    <citation>Temple ME, Nahata MC. Treatment of listeriosis. Ann Pharmacother. 2000 May;34(5):656-61. Review.</citation>
    <PMID>10852095</PMID>
  </reference>
  <reference>
    <citation>Hof H. Listeriosis: therapeutic options. FEMS Immunol Med Microbiol. 2003 Apr 1;35(3):203-5. Review.</citation>
    <PMID>12648838</PMID>
  </reference>
  <reference>
    <citation>Personal communication with Professor Jeremy Farrar, Director, Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.</citation>
  </reference>
  <reference>
    <citation>West TE, Chantratita N, Chierakul W, Limmathurotsakul D, Wuthiekanun V, Myers ND, Emond MJ, Wurfel MM, Hawn TR, Peacock SJ, Skerrett SJ. Impaired TLR5 functionality is associated with survival in melioidosis. J Immunol. 2013 Apr 1;190(7):3373-9. doi: 10.4049/jimmunol.1202974. Epub 2013 Feb 27.</citation>
    <PMID>23447684</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2014</study_first_posted>
  <last_update_submitted>February 17, 2016</last_update_submitted>
  <last_update_submitted_qc>February 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

